Lazabemide
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H10ClN3O
Molar mass199.64 g·mol−1

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]

References

  1. ^ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". Amine Oxidases: Function and Dysfunction. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245. ((cite book)): |journal= ignored (help)


Categories